Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) had its price target boosted by investment analysts at JMP Securities from $40.00 to $63.00 in a report issued on Friday, The Fly reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. JMP Securities’ price objective would suggest a potential upside of 25.72% from the stock’s previous close.

Separately, Evercore ISI began coverage on shares of Madrigal Pharmaceuticals in a report on Friday, September 22nd. They set an “outperform” rating and a $65.00 price objective for the company.

Shares of Madrigal Pharmaceuticals (NASDAQ MDGL) opened at 50.11 on Friday. The stock’s market cap is $626.12 million. The firm’s 50-day moving average price is $29.01 and its 200-day moving average price is $19.00. Madrigal Pharmaceuticals has a 52-week low of $13.09 and a 52-week high of $51.53.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.09). Equities analysts predict that Madrigal Pharmaceuticals will post ($2.67) EPS for the current year.

WARNING: This news story was first reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/13/madrigal-pharmaceuticals-inc-mdgl-pt-raised-to-63-00.html.

In other Madrigal Pharmaceuticals news, Director Richard S. Levy purchased 2,000 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The stock was purchased at an average price of $16.12 per share, with a total value of $32,240.00. Following the acquisition, the director now owns 7,200 shares in the company, valued at $116,064. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard S. Levy purchased 3,550 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was acquired at an average cost of $15.88 per share, with a total value of $56,374.00. Following the acquisition, the director now owns 900 shares in the company, valued at approximately $14,292. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 9,100 shares of company stock valued at $145,840. 66.40% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in the stock. Rock Springs Capital Management LP bought a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at about $799,000. Renaissance Technologies LLC lifted its holdings in shares of Madrigal Pharmaceuticals by 0.7% in the 1st quarter. Renaissance Technologies LLC now owns 57,875 shares of the biopharmaceutical company’s stock valued at $891,000 after acquiring an additional 400 shares during the last quarter. Baker BROS. Advisors LP bought a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at about $732,000. Northern Trust Corp lifted its holdings in shares of Madrigal Pharmaceuticals by 151.2% in the 2nd quarter. Northern Trust Corp now owns 50,069 shares of the biopharmaceutical company’s stock valued at $814,000 after acquiring an additional 30,134 shares during the last quarter. Finally, State Street Corp bought a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at about $539,000. 16.39% of the stock is owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

The Fly

Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.